Lilly’s investment plans in India come at a time when global drugmakers are rushing to bolster US manufacturing capacity after the Trump administration imposed a 100% tariff on imported branded and patented drugs from October 1.
Lilly’s investment plans in India come at a time when global drugmakers are rushing to bolster US manufacturing capacity after the Trump administration imposed a 100% tariff on imported branded and patented drugs from October 1.